Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.
Earnings and Valuation
This table compares Aurinia Pharmaceuticals and Cardio Diagnostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | 7.67 | $287.20 million | $2.29 | 7.08 |
| Cardio Diagnostics | $10,000.00 | 495.80 | -$6.50 million | ($2.92) | -0.57 |
Aurinia Pharmaceuticals has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aurinia Pharmaceuticals and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
Analyst Ratings
This is a breakdown of recent ratings for Aurinia Pharmaceuticals and Cardio Diagnostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 3 | 1 | 2.71 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Aurinia Pharmaceuticals presently has a consensus price target of $18.25, suggesting a potential upside of 12.58%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Cardio Diagnostics.
Institutional and Insider Ownership
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500.
Summary
Aurinia Pharmaceuticals beats Cardio Diagnostics on 13 of the 15 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
